companiesCompany
Avenzo Therapeutics
Avenzo in-licenses Chinese assets, including the Nectin-4×TROP2 bispecific ADC AVZO-103 and a CDK2 inhibitor.
AVZO-103 (Nectin-4×TROP2 bsADC), AVZO-021 (CDK2), AVZO-1418 (EGFR×HER3 ADC).
Pages like this
not linked directly; found by shared links- ProductAK146D1
Shares Nectin-4, Bispecific ADC, TROP2.
- TermOverexpression
- RoadmapTROP2 ADC roadmap: sacituzumab govitecan → Dato-DXd → sac-TMT → bispecifics and PET
Shares Bispecific ADC, TROP2.